Physics for practitioners: the use of radiolabeled monoclonal antibodies in B-cell non-Hodgkin's lymphoma.
Semin Hematol
; 37(4 Suppl 7): 2-8, 2000 Oct.
Article
em En
| MEDLINE
| ID: mdl-11147486
ABSTRACT
The limitations of conventional treatment for non-Hodgkin's lymphoma (NHL) have led to intense investigations of biological therapies for this disease, including monoclonal antibodies. Conjugation of these antibodies with radionuclides results in additional cytotoxic activity with generally acceptable levels of toxicity. Numerous antibodies and radionuclides of widely varying properties are in clinical development. Given the likelihood that one or more radioimmunotherapeutic agents will soon be commercially available, there is a need for oncologists who treat patients with NHL to become more aware of the principles of radiation physics that underlie radioimmunotherapy and the interactions among radiolabeled antibodies, the tumor, and the host.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Linfoma de Células B
/
Radioimunoterapia
/
Anticorpos Monoclonais
Idioma:
En
Ano de publicação:
2000
Tipo de documento:
Article